Novel useful markers for follow-up of necrotizing enterocolitis: endocan and interleukin-33

References

• Lim JC, Golden JM, Ford HR. Pathogenesis of neonatal necrotizing enterocolitis. Pediatr Surg Int. 2015;31:509–518.
   PubMed Web of Science ®Google Scholar
• Upperman JS, Camerini V, Lugo B, et al. Mathematical modeling in necrotizing enterocolitis – a new look at an ongoing problem. J Pediatr Surg. 2007;42:445–453.
   PubMed Web of Science ®Google Scholar
• De Plaen IG. Inflammatory signaling in necrotizing enterocolitis. Clin Perinatol. 2013;40:109–124.
   PubMed Web of Science ®Google Scholar
• Niño DF, Sodhi CP, Hackam DJ. Necrotizing enterocolitis: new insights into pathogenesis and mechanisms. Nat Rev Gastroenterol Hepatol. 2016;13:590–600.
   PubMed Web of Science ®Google Scholar
• Zhang SM, Zuo L, Zhou Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem. 2012;87:172–178.
   PubMed Web of Science ®Google Scholar
• Zuo L, Zhang SM, Hu RL, et al. Correlation between expression and differentiation of endocan in colorectal cancer. Wjg. 2008;14:4562–4568.
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Depontieu F, Grigoriu B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med. 2006;34:532–537.
   PubMed Web of Science ®Google Scholar
• Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? Plos One. 2008;3:e3331.
   PubMed Web of Science ®Google Scholar
• Beltrán CJ, Núñez LE, Díaz-Jiménez D, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1097–1107.
   PubMed Web of Science ®Google Scholar
• Kobori A, Yagi Y, Imaeda H, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45:999–1007.
   PubMed Web of Science ®Google Scholar
• Masterson JC, Capocelli KE, Hosford L, et al. Eosinophils and IL-33 perpetuate chronic inflammation and fibrosis in a pediatric population with stricturing Crohn’s ileitis. Inflamm Bowel Dis. 2015;21:2429–2440.
   PubMed Web of Science ®Google Scholar
• Nunes T, Bernardazzi C, de Souza HS. Interleukin-33 and inflammatory bowel diseases: lessons from human studies. Mediators Inflamm. 2014;2014:1–10.
   Web of Science ®Google Scholar
• Garg BD, Sharma D, Bansal A. Biomarkers of necrotizing enterocolitis: a review of literature. J Matern Fetal Neonatal Med. 2018;31:3051–3064.
   PubMed Web of Science ®Google Scholar
• Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic Decisions Based upon Clinical Staging. Ann Surg. 1978;187:1–7.
   PubMed Web of Science ®Google Scholar
• Papile LA, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92:529–534.
   PubMed Web of Science ®Google Scholar
• Northway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. N Engl J Med. 1967;276:357–368.
   PubMed Web of Science ®Google Scholar
• Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986;33:179–201.
   PubMed Web of Science ®Google Scholar
• Tayman C, Aydemir S, Yakut I, et al. TNF-α blockade efficiently reduced severe intestinal damage in necrotizing enterocolitis. J Invest Surg. 2016;29:209–217.
   PubMed Web of Science ®Google Scholar
• Hunter CJ, De Plaen IG. Inflammatory signaling in NEC: role of NF-κB, cytokines and other inflammatory mediators. Pathophysiology. 2014;21:55–65.
   PubMedGoogle Scholar
• Marshall JC, Vincent JL, Fink MP, et al. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25–26, 2000. Crit Care Med. 2003;31:1560–1567.
   PubMed Web of Science ®Google Scholar
• Towfigh S, Heisler T, Rigberg DA, et al. Intestinal ischemia and the gut-liver axis: an in vitro model. J Surg Res. 2000;88:160–164.
   PubMed Web of Science ®Google Scholar
• Morecroft JA, Spitz L, Hamilton PA, et al. Plasma cytokine levels in necrotizing enterocolitis. Acta Paediatr Suppl. 1994; 83:18–20.
   PubMedGoogle Scholar
• Tayman C, Tonbul A, Kahveci H, et al. C5a, a complement activation product, is a useful marker in predicting the severity of necrotizing enterocolitis. Tohoku J Exp Med. 2011;224:143–150.
   PubMed Web of Science ®Google Scholar
• Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37:417–425.
   PubMed Web of Science ®Google Scholar
• Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458–20464.
   PubMed Web of Science ®Google Scholar
• Lee W, Ku SK, Kim SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229:620–630.
   PubMed Web of Science ®Google Scholar
• Zuwala-Jagiello J, Simon K, Kukla M, et al. Increased circulating endocan in patients with cirrhosis: relation to bacterial infection and severity of disease. J Physiol Pharmacol. 2017;68:273–282.
   PubMed Web of Science ®Google Scholar
• Yeh YC, Wu CY, Cheng YJ, et al. Effects of dexmedetomidine on intestinal microcirculation and intestinal epithelial barrier in endotoxemic rats. Anesthesiology. 2016;125:355–367.
   PubMed Web of Science ®Google Scholar
• Voiosu T, Bălănescu P, Benguş A, et al. Serum endocan levels are increased in patients with inflammatory bowel disease. Clin Lab. 2014;60:505–510.
   PubMed Web of Science ®Google Scholar
• Atis O, Keles M, Cankaya E, et al. Vitamin D treatment effect on serum endocan and high-sensitivity C-reactive protein levels in renal transplant patients. Prog Transpl. 2016;26:335–339.
   PubMed Web of Science ®Google Scholar
• Ioakeimidou A, Pagalou E, Kontogiorgi M, et al. Hellenic Sepsis Study Group. Increase of circulating endocan over sepsis follow-up is associated with progression into organ dysfunction. Eur J Clin Microbiol Infect Dis. 2017;36:1749–1756.
   PubMed Web of Science ®Google Scholar
• Pastorelli L, De Salvo C, Cominelli MA, et al. Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap Adv Gastroenterol. 2011;4:311–323.
   PubMedGoogle Scholar
• Seidelin JB, Bjerrum JT, Coskun M, et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett. 2010;128:80–85.
   PubMed Web of Science ®Google Scholar
• Pastorelli L, Garg RR, Hoang SB, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA. 2010;107:8017–8022.
   PubMed Web of Science ®Google Scholar
• Komai-Koma M, Xu D, Li Y, et al. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779–2786.
   PubMed Web of Science ®Google Scholar
• Talabot-Ayer D, Lamacchia C, Gabay C, et al. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem. 2009;284:19420–19426.
   PubMed Web of Science ®Google Scholar